Prognostic importance of comorbidity in a hospital-based cancer registry

JAMA

Volumn 291, Issue 20, 2004, Pages 2441-2447

  Piccirillo, Jay F ^a,b,d   Tierney, Ryan M ^b   Costas, Irene ^a,d   Grove, Lori ^c,d   Spitznagel, Edward L ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; COMORBIDITY; DIGESTIVE SYSTEM CANCER; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; SYSTEMATIC REVIEW; URINARY TRACT CANCER; MIDDLE AGED; MORTALITY; NEOPLASM; REGISTER; SURVIVAL;

ADULT; AGED; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; REGISTRIES; SURVIVAL ANALYSIS;

EID: 2442696436     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.20.2441     Document Type: Article

References (46)

1. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 1996;77:834-842.
2. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970; 23:455-469.
3. Newschaffer CJ, Penberthy L, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med. 1996;156:85-90.
4. Schrijvers CM, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 1997;80:1482-1488.
5. Yancik R, Wesley MN, Ries LG, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-2134.
6. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities. Med Care. 1999;37: 601-614.
7. Yates JW. Comorbidity considerations in geriatric oncology research. CA Cancer J Clin. 2001;51:329-336.
8. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes. Ann Arbor, Mich: Health Administration Press; 1994.
9. Satariano WA. Comorbidities and cancer. In: Hunter CP, Johnson KA, Muss HB, eds. Cancer in the Elderly. New York, NY: Marcel Dekker; 2000:477-499.
10. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35:181-200.
11. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996;156:127-132.
12. Piccirillo JF, Wells CK, Sasaki CT, Feinstein AR. New clinical severity staging system for cancer of the larynx: five-year survival rates. Ann Otol Rhinol Laryngol. 1994;103:83-92.
13. Piccirillo JF. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology. 1995; 9:831-836.
14. Hall SF, Groome PA, Rothwell D. The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head Neck. 2000;22:317-322.
15. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol. 2003;169:105-109.
16. DiSilvestro P, Peipert JF, Hogan JW, Granai CO. Prognostic value of clinical variables in ovarian cancer. J Clin Epidemiol. 1997;50:501-505.
17. Wells CK, Stoller JK, Feinstein AR, Horwitz RI. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med. 1984;144:2004-2009.
18. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104-110.
19. Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885-892.
20. van Spronsen DJ, Janssen-Heijnen MG, Breed WM, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999;78:315-319.
21. Morrow M, Sylvester J, DesHarnais S. CoC and NCDB to examine approaches to classifying comorbidities: news from the Commission on Cancer. J Am Coll Surg. 2000;11:2-3.
22. Cancer Dataset Project/Pilot Lessons Learned Report. Available at: http://www.nhsia.nhs.uk/cancer /pages/dataset/docs/cdp_lessons_learned_comorbidity .pdf. Accessibility verified April 19, 2004.
23. Commission on Cancer. Registry Operations and Data Standards (ROADS). Vol II. Chicago, Ill: American College of Surgeons; 1999.
24. Piccirillo JF, Creech CM, Zequeira R, Anderson S, Johnston AS. Inclusion of comorbidity into oncology data registries. J Registry Manage. 1999;26:66-70.
25. Malenka DJ, McLerran D, Roos N, Fisher ES, Wennberg JE. Using administrative data to describe casemix: a comparison with the medical record. J Clin Epidemiol. 1994;47:1027-1322.
26. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387-404.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
28. Elixhauser A, Steiner C, Harris R, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
29. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
30. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D. The measurement of comorbidity by cancer registries. J Registry Manage. 2003;30:8-14.
31. National Death Index. Available at: http://www .cdc.gov/nchs/r& d/ndi/ndi.htm. Accessibility verified April 21, 2004.
32. Stata Statistcal Software: Release 7.0. College Station, Tex: Stata Corp; 2001:394-400.
33. Harrell FEJ, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
34. Harrell FEJ. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2001.
35. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299-305.
36. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: comorbidity and outcomes after hip replacement. Med Care. 1993;31:141-154.
37. Commission on Cancer, Facility Operations and Data Standards (FORDS). Section One: Case Eligibility, Cancer Identification, and Overview of Coding Principles. Chicago, Ill: American College of Surgeons; 2003:1-28.
38. International Classification of Diseases, Ninth Revision, Clinical Modification. 5th ed. Los Angeles, Calif: Practice Management Information Corp; 1996.
39. Concato J, Elmore JG, Horwitz RI, Schiff SF, Feinstein AR. Severity of comorbidity, not type of surgery, affects outcome of prostatectomy. Trans Assoc Am Physicians. 1990;103:90-95.
40. Iezzoni LI, Shwartz M, Ash AS, Mackiernan Y, Hotchkin EK. Risk adjustment methods can affect perceptions of outcomes. Am J Med Qual. 1994;9:43-48.
41. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. A comparison of the Charlson Comorbidity Index derived from medical record data and administrative billing data. J Clin Epidemiol. 1998;52:137-142.
42. Iezzoni LI. The risks of risk adjustment. JAMA. 1997;278:1600-1607.
43. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996;34:152-162.
44. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19:1147-1151.
45. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110:593-602.
46. Piccirillo J. The impact of comorbidity in head and neck cancer. J Registry Manage. 2001;28:172-176.